Comprehensive genomic profiles of small cell lung cancer
- PMID: 26168399
- PMCID: PMC4861069
- DOI: 10.1038/nature14664
Comprehensive genomic profiles of small cell lung cancer
Abstract
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Δex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
Figures
![Extended Data Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f6.gif)
![Extended Data Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f7.gif)
![Extended Data Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f8.gif)
![Extended Data Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f9.gif)
![Extended Data Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f10.gif)
![Extended Data Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f11.gif)
![Extended Data Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f12.gif)
![Extended Data Figure 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f13.gif)
![Extended Data Figure 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f14.gif)
![Extended Data Figure 10](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f15.gif)
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4861069/bin/nihms782739f5.gif)
Similar articles
-
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.Int J Cancer. 2016 Feb 15;138(4):927-38. doi: 10.1002/ijc.29835. Epub 2015 Sep 25. Int J Cancer. 2016. PMID: 26340530 Free PMC article.
-
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.Mol Oncol. 2021 Jan;15(1):27-42. doi: 10.1002/1878-0261.12673. Epub 2020 Nov 25. Mol Oncol. 2021. PMID: 32191822 Free PMC article.
-
Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.Lung Cancer. 2018 Dec;126:182-188. doi: 10.1016/j.lungcan.2018.11.014. Epub 2018 Nov 12. Lung Cancer. 2018. PMID: 30527185
-
Small-cell lung cancer: what we know, what we need to know and the path forward.Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Nat Rev Cancer. 2017. PMID: 29077690 Review.
-
Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.Hum Cell. 2017 Jan;30(1):1-10. doi: 10.1007/s13577-016-0149-3. Epub 2016 Oct 26. Hum Cell. 2017. PMID: 27785690 Review.
Cited by
-
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nat Rev Clin Oncol. 2024 Aug;21(8):610-627. doi: 10.1038/s41571-024-00914-x. Epub 2024 Jul 4. Nat Rev Clin Oncol. 2024. PMID: 38965396 Review.
-
Genetic tracing uncovers the importance of epithelial-to-mesenchymal transition in small cell lung cancer chemotherapy resistance but not metastasis.Cell Discov. 2024 Jun 4;10(1):60. doi: 10.1038/s41421-024-00687-8. Cell Discov. 2024. PMID: 38834595 Free PMC article. No abstract available.
-
Comprehensive multi-omics analysis provides biological insights and therapeutic strategies for small-cell lung cancer.MedComm (2020). 2024 May 29;5(6):e569. doi: 10.1002/mco2.569. eCollection 2024 Jun. MedComm (2020). 2024. PMID: 38817653 Free PMC article.
-
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x. Mol Cancer. 2024. PMID: 38811992 Free PMC article. Clinical Trial.
-
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x. Signal Transduct Target Ther. 2024. PMID: 38797752 Free PMC article. Review.
References
-
- van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–1755. - PubMed
-
- Takahashi T, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246:491–494. - PubMed
-
- Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin. Oncol. 2001;28:3–13. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous